Admission to AIM

Futura Medical PLC
22 July 2003


Press Release                                                       22 July 2003


Futura Medical plc joins AIM



Futura Medical plc ('Futura Medical', 'Futura' or 'the Company'), the
pharmaceutical and medical device group that develops innovative products for
the sexual healthcare market, is today admitted to trading on the Alternative
Investment Market (AIM) of the London Stock Exchange.



The Company has recently raised the sum of £1.7 million conditional on its
admission to AIM by way of a private cash subscription for 2,428,571 new
ordinary shares at a price of 70 pence per share, giving an implied market
capitalisation of approximately £30 million.



Dr Bill Potter, Non-executive Chairman of Futura Medical, said: 'The Company is
led by a strong management team with extensive experience in commercial and
pharmaceutical development, supported by a Medical Advisory Board comprising
recognised experts.  The Company's product portfolio and partnership approach
makes it ideally placed to exploit the enormous potential within the sexual
health and well-being market.'



James Barder, Chief Executive of Futura Medical, said: 'We are delighted that
our most recent fund raising and admission to AIM have been so successful.
Futura's principal products are at an exciting stage of development and the
Company continues to identify opportunities to complement its expanding product
portfolio.'



Based at the Surrey Research Park in Guildford, Futura Medical is developing a
number of innovative products in the field of sexual healthcare.  A key part of
the Company's strategy is identifying international sales, distribution and
marketing partners for the products.  The Company will initially focus on
exploiting its current portfolio.



The first product, MED2001, is a rub-on vasodilator cream for the treatment of
male erectile dysfunction.  It may also satisfy a currently unmet clinical need
among angina sufferers, since currently available erectile dysfunction
treatments taken orally cannot be used with nitrate-based angina drugs.  A Phase
II study of MED2001 has been completed and early indications suggest a high
level of safety.  A conditional distribution agreement has been entered into
with Goldshield plc.



Futura is also developing CSD500, a condom that incorporates an
erection-enhancing compound aimed at reducing the likelihood of potential
slippage.  A robust development programme has been undertaken to address the
requirements of EU regulators.  The regulatory dossier is scheduled for
submission in early 2004.  A conditional exclusive worldwide distribution
agreement has been signed.  Futura believes CSD500 will encourage greater condom
use by healthy men.



The Company has two other products at earlier stages of development to enhance
male and female sexual health and well being.



Williams de Broe Plc are both Nominated Adviser and Broker to the Company.  The
solicitors to the Company are Memery Crystal; the accountants are BDO Stoy
Hayward.



                                    - Ends -



For further information:
Futura Medical plc
James Barder, Chief Executive                                                         Tel: [phone]
[e-mail]                                                         www.futuramedical.co.uk


Williams de Broe Plc
Clive Carver, Corporate Finance                                                       Tel: [phone]



Media Enquiries:

Bankside
Peter Curtain / Russell Elliott                                                       Tel: [phone]
[e-mail]                                                                   www.bankside.com



Photography

Photography is available from Bankside.  To arrange, please contact Russell
Elliott on [phone] or [e-mail]




Notes to editors:



Futura Medical is a pharmaceutical and medical device group developing
innovative products for sexual health.  The group has a portfolio of products in
various stages of development.



The products are expected to be a combination of prescription-only and
over-the-counter (OTC).  However, Futura's primary focus is on OTC products,
with particular appeal to men and women who are reluctant to discuss potentially
embarrassing sexual matters with their doctors.



In June 2003, the Company's first product, MED2001, a rub-on cream for erectile
dysfunction (ED), completed its Phase II study, which demonstrated a good safety
profile.  MED2001 is likely to commence further clinical programmes later in
2003, prior to a regulatory submission for licensing in 2004.



Futura intends shortly to begin a trial to assess the safety of MED2001 in
angina patients.  Normal medications taken by angina patients prevent the use of
most current ED treatments.



Futura is developing a portfolio of products with the intention of licensing
their manufacture and distribution to major pharmaceutical groups.  Several
agreements have already been signed.



The British Journal of Urology estimates that sexual dysfunction will affect
more than 300 million people worldwide by 2025.


                      This information is provided by RNS
            The company news service from the London Stock Exchange